Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma

Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma

Prognostic tests for patients with early-stage lung cancer may provide needed guidance on postoperative surveillance and therapeutic decisions. We used a novel strategy to develop and validate a prognostic classifier for early-stage lung cancer. Specifically, we focused on 42 genes with roles in lun...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Ichiro Akagi, Hirokazu Okayama, Aaron J. Schetter, Ana I. Robles, Takashi Kohno, Elise D. Bowman, Dickran Kazandjian, Judith A. Welsh, Naohide Oue, Motonobu Saito, Masao Miyashita, Eiji Uchida, Toshihiro Takizawa, Seiichi Takenoshita, Vidar Skaug, Steen Mollerup, Aage Haugen, Jun Yokota, Curtis C. Harris
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2013
Urunga tuihono:	https://doi.org/10.1158/0008-5472.can-13-0031
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma
mā: Akagi, Ichiro, me ētahi atu.
I whakaputaina: (2013)

The association of microRNA expression with prognosis and progression in early stage, non small cell lung adenocarcinoma: a retrospective analysis of three cohorts
mā: Saito, Motonobu, me ētahi atu.
I whakaputaina: (2011)

The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts
mā: Motonobu Saito, me ētahi atu.
I whakaputaina: (2011)

DNA methylation of the CYP1A1 enhancer is associated with smoking‐induced genetic alterations in human lung
mā: Xavier Tekpli, me ētahi atu.
I whakaputaina: (2011)

A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts
mā: Noro, Rintaro, me ētahi atu.
I whakaputaina: (2016)

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma based on mRNA, microRNA and DNA Methylation Biomarkers
mā: Robles, Ana I., me ētahi atu.
I whakaputaina: (2015)

The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts
mā: Okayama, Hirokazu, me ētahi atu.
I whakaputaina: (2014)

NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression
mā: Okayama, Hirokazu, me ētahi atu.
I whakaputaina: (2012)

An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
mā: Ana I. Robles, me ētahi atu.
I whakaputaina: (2015)

NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression
mā: Hirokazu Okayama, me ētahi atu.
I whakaputaina: (2012)

Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women
mā: Susan Olivo‐Marston, me ētahi atu.
I whakaputaina: (2010)

Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women
mā: Olivo-Marston, Susan E., me ētahi atu.
I whakaputaina: (2010)

Gene variants and lung cancer risk
mā: Landvik, Nina E, me ētahi atu.
I whakaputaina: (2010)

Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer
mā: Samulin Erdem, Johanna, me ētahi atu.
I whakaputaina: (2016)

Gene aberrations for precision medicine against lung adenocarcinoma
mā: Saito, Motonobu, me ētahi atu.
I whakaputaina: (2016)

Gene aberrations for precision medicine against lung adenocarcinoma
mā: Motonobu Saito, me ētahi atu.
I whakaputaina: (2016)

Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines
mā: Heidi Uppstad, me ētahi atu.
I whakaputaina: (2009)

Association of a functional polymorphism in the promoter of the <i>MDM2</i> gene with risk of nonsmall cell lung cancer
mā: Helge Lind, me ētahi atu.
I whakaputaina: (2006)

Copy number variation, increased gene expression, and molecular mechanisms of neurofascin in lung cancer
mā: Samulin Erdem, Johanna, me ētahi atu.
I whakaputaina: (2017)

Polymorphisms of the interleukin‐1 β gene are associated with increased risk of non‐small cell lung cancer
mā: Shanbeh Zienolddiny, me ētahi atu.
I whakaputaina: (2004)

Effects of carbon nanotubes on intercellular communication and involvement of IL-1 genes
mā: Arnoldussen, Yke Jildouw, me ētahi atu.
I whakaputaina: (2016)

Multiple myeloma epidemiology and survival, a unique malignancy
mā: Kazandjian, Dickran
I whakaputaina: (2016)

Multiple myeloma epidemiology and survival: A unique malignancy
mā: Dickran Kazandjian
I whakaputaina: (2016)

CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer
mā: Saito, Motonobu, me ētahi atu.
I whakaputaina: (2017)

DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer
mā: Xavier Tekpli, me ētahi atu.
I whakaputaina: (2012)

A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers
mā: Shanbeh Zienolddiny, me ētahi atu.
I whakaputaina: (2008)

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
mā: Kazandjian, Dickran, me ētahi atu.
I whakaputaina: (2016)

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime
mā: Kazandjian, Dickran, me ētahi atu.
I whakaputaina: (2019)

Diagnosed with myeloma before age 40
mā: Landgren, Ola, me ētahi atu.
I whakaputaina: (2021)

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
mā: Dickran Kazandjian, me ētahi atu.
I whakaputaina: (2016)

Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer
mā: Nakajima, Takahiro, me ētahi atu.
I whakaputaina: (2018)

Long-term Outcomes of Lower Rectal Cancer Patients Treated with Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection after Preoperative Radiotherapy or Chemoradiotherapy
mā: Sakamoto, Wataru, me ētahi atu.
I whakaputaina: (2021)

A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
mā: Saito, Motonobu, me ētahi atu.
I whakaputaina: (2014)

Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
mā: Shanbeh Zienolddiny, me ētahi atu.
I whakaputaina: (2005)

KIF5B-RET fusions in lung adenocarcinoma
mā: Kohno, Takashi, me ētahi atu.
I whakaputaina: (2012)

KIF5B-RET fusions in lung adenocarcinoma
mā: Takashi Kohno, me ētahi atu.
I whakaputaina: (2012)

Overexpression of endoglin (CD105) is associated with recurrence in radically resected gastric cancer
mā: KOYAMA, YOSHIHISA, me ētahi atu.
I whakaputaina: (2010)

Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
mā: Aoto, Keita, me ētahi atu.
I whakaputaina: (2018)

Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma
mā: Keita Aoto, me ētahi atu.
I whakaputaina: (2017)

Expression of circadian clock genes in human colorectal adenoma and carcinoma
mā: Momma, Tomoyuki, me ētahi atu.
I whakaputaina: (2017)